• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Introduction to 1-(2-fluoroethyl)-1H-pyrazol-5-amine (CAS No. 689295-20-3) and Its Emerging Applications in Chemical Biology and Medicinal Chemistry

1-(2-fluoroethyl)-1H-pyrazol-5-amine, identified by the chemical identifier CAS No. 689295-20-3, is a heterocyclic organic compound that has garnered significant attention in the fields of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This compound belongs to the pyrazole class, which is well-documented for its broad spectrum of biological activities, including anti-inflammatory, antimicrobial, and anticancer effects. The presence of a fluoroethyl side chain in its molecular structure introduces additional functional flexibility, making it a valuable scaffold for drug discovery and development.

The fluoroethyl group is particularly noteworthy in medicinal chemistry, as fluorine atoms can modulate the pharmacokinetic and pharmacodynamic properties of molecules. Fluorinated compounds often exhibit improved metabolic stability, enhanced binding affinity to biological targets, and altered pharmacological profiles compared to their non-fluorinated counterparts. In the case of 1-(2-fluoroethyl)-1H-pyrazol-5-amine, the fluorine atom is positioned at the 2-position of the ethyl chain, which can influence both electronic and steric interactions within the molecule. This structural feature has been leveraged in various research endeavors to develop novel bioactive entities.

Recent advancements in computational chemistry and structure-based drug design have further highlighted the significance of 1-(2-fluoroethyl)-1H-pyrazol-5-amine as a lead compound. High-throughput virtual screening (HTVS) and molecular docking studies have demonstrated its potential as an inhibitor of several key enzymes implicated in diseases such as cancer and inflammation. For instance, preliminary studies suggest that this compound may interact with enzymes involved in polyamine metabolism, which is a critical pathway in cell growth and differentiation. The fluoroethyl moiety is believed to enhance binding interactions by improving hydrophobicity and reducing desolvation penalties during enzyme-substrate complex formation.

In the realm of oncology, pyrazole derivatives have shown promise as kinase inhibitors due to their ability to disrupt aberrant signaling pathways that drive tumor progression. 1-(2-fluoroethyl)-1H-pyrazol-5-amine has been investigated for its potential to inhibit tyrosine kinases, which are overexpressed in many solid tumors and contribute to uncontrolled cell proliferation. The fluoroethyl group may enhance binding affinity by occupying hydrophobic pockets within the kinase active site, thereby stabilizing the enzyme-inhibitor complex. Furthermore, fluorine atoms can participate in favorable dipole-dipole interactions with aromatic residues in the target protein, further reinforcing binding specificity.

Beyond its applications in oncology, 1-(2-fluoroethyl)-1H-pyrazol-5-amine has also been explored for its anti-inflammatory properties. Pyrazole derivatives are known to modulate inflammatory pathways by inhibiting key mediators such as cyclooxygenase (COX) and lipoxygenase (LOX). The structural motif of this compound allows for selective interaction with these enzymes without significant off-target effects. The fluoroethyl group may enhance binding affinity by optimizing steric complementarity with subsite pockets in COX enzymes, leading to potent inhibition of prostaglandin synthesis—a major pro-inflammatory molecule.

Another area where 1-(2-fluoroethyl)-1H-pyrazol-5-amine has shown promise is in central nervous system (CNS) disorders. Pyrazole derivatives have been reported to cross the blood-brain barrier (BBB) efficiently, making them suitable candidates for treating neurological conditions such as epilepsy and neurodegenerative diseases. The fluoroethyl group may facilitate BBB penetration by enhancing lipophilicity while maintaining metabolic stability. Preclinical studies have indicated that this compound may exert neuroprotective effects by modulating neurotransmitter systems involved in synaptic plasticity and neuronal survival.

The synthesis of 1-(2-fluoroethyl)-1H-pyrazol-5-amine presents an interesting challenge due to the need for precise functionalization at multiple positions on the pyrazole core. Advanced synthetic methodologies, including transition-metal-catalyzed cross-coupling reactions and fluorination techniques, have been employed to achieve high yields and purity. These synthetic strategies not only enhance scalability but also allow for rapid diversification of the molecular scaffold through library synthesis approaches. Such methodologies are crucial for accelerating drug discovery pipelines by generating structurally diverse compounds for screening.

The pharmacokinetic profile of 1-(2-fluoroethyl)-1H-pyrazol-5-amine has been carefully evaluated using in vitro and in vivo models. Preliminary data suggest that this compound exhibits favorable absorption, distribution, metabolism, excretion (ADME) properties suitable for clinical development. The fluoroethyl group contributes to improved oral bioavailability by enhancing lipophilicity while minimizing susceptibility to metabolic degradation by cytochrome P450 enzymes. Additionally, fluorine atoms can increase molecular rigidity, reducing susceptibility to enzymatic hydrolysis—a desirable property for long-term therapeutic efficacy.

In conclusion,1-(2-fluoroethyl)-1H-pyrazol-5-amine (CAS No. 689295-20-3) represents a promising lead compound with diverse applications across multiple therapeutic areas. Its unique structural features—particularly the presence of a fluoroethyl side chain—make it an attractive scaffold for medicinal chemists seeking to develop novel bioactive molecules. Ongoing research efforts are focused on optimizing its pharmacological properties through structure-based design principles and exploring its potential as a therapeutic agent in unmet medical needs such as cancer treatment and neuroprotection.

• 3528-58-3(1-Ethyl-1H-pyrazol-5-amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)